KalshiCheck availabilityKYC required2% feeVerified resolution dataFairly calibratedCurrent implied probability
Yes 97%+30.0pt
Market quality
45 / 100
Low quality24h Volume
$626.9
Liquidity
$690.6
Low liquidityBid / Ask
72.0% / 80.0%
Spread
8.0 pt
Wide spreadMarket data
Updated 6 minutes ago
Jun 17, 26, 9:30 PM UTCJan 1, 27, 4:59 AM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRules
If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Settles via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
- Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
- In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.
Open markets
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Total Vol
- $18.1M
- 24h Vol
- $22.1K
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Total Vol
- $1.9M
- 24h Vol
- $6K
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 more outcomes
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Total Vol
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Total Vol
- $1.1M
- 24h Vol
- $1.8K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000-1.0pt96%
- Above 6000+1.0pt60%
+2 more outcomes
- Total Vol
- $1M
- 24h Vol
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- When will the FDA reclassify BPC-157 to Category 1?
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
Frequently asked questions
- What are the current odds for FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)?
- Kalshi prices Yes at 97% as of September 8, 2026.
- When does FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) resolve?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) is scheduled to resolve on January 1, 2027.
- How is FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) settled?
- Kalshi settles this market as follows: If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.